使用单一歧管装置行胸腹主动脉瘤修复术
单中心前瞻性研究纳入2015至2023年连续126例胸腹主动脉瘤患者,由同一医生在医生发起研究豁免下使用医生修改的非解剖型单一歧管装置行腔内修复。技术成功率99.2%,365天动脉瘤相关死亡率4.0%,全因死亡率16.7%,分支一期通畅率高。
要点
- 连续126例胸腹主动脉瘤患者使用医生修改的非解剖型单一歧管装置行腔内修复,技术成功率99.2%。
- 365天动脉瘤相关死亡率4.0%,全因死亡率16.7%,持续截瘫发生率0.8%。
- 444条分支支架中仅3例(2.4%)因分支通畅丧失需再干预,365天再干预率5.6%。
核心结论
- 单一歧管装置表现出显著的技术成功、治疗成功和装置通畅率,主要不良事件和再干预率合理。
- 本研究纳入126例连续全来者患者,病理多样,与其他现成装置研究相比更具普通人群代表性。
研究设计与样本
- 单中心前瞻性研究,纳入2015至2023年连续126例接受医生修改的非解剖型单一歧管装置腔内修复的胸腹主动脉瘤患者。
- 治疗由同一医生在医生发起研究豁免G140207下完成,纳入所有Crawford范围包括近肾、肾旁及短颈(<10 mm)肾下动脉瘤。
- 不因临床表现、动脉瘤或夹层范围或脊髓事件史排除患者。
主要发现
- Crawford分型:I和V型3.3%(n=4),II型3.3%(n=4),III型1%(n=1),IV型93.3%(n=117);IV型中真性IV型33例(28.2%)、肾旁或肾下68例(58.1%)、夹层16例(13.7%)。
- 技术成功率99.2%(n=125)。
- 30天和365天最常见主要不良事件均为呼吸衰竭,分别为11.9%(n=15)和13.5%(n=17)。
- 365天持续截瘫1例(0.8%),再干预率5.6%(n=7)。
- 444条分支支架中3例(2.4%)因分支通畅丧失需再干预,动脉瘤增大(≥5 mm)1.6%(n=2),无动脉瘤破裂,无转为开放修复,未观察到装置完整性失败。
关键数值与推荐
- 技术成功定义为99.2%(n=125)。
- 365天动脉瘤相关死亡率4.0%(n=5),全因死亡率16.7%(n=21)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To present a single-center prospective study of 126 consecutively treated patients who underwent endovascular repair of a thoracoabdominal aortic aneurysm with the physician-modified, nonanatomic-based Unitary Manifold (UM) device. METHODS: Data were collected from 126 consecutive all-comer patients treated with the physician-modified, nonanatomic-based UM from 2015 to 2023. Treatment was performed at a single center by a single physician under a Physician Sponsored Investigation Exemption G140207. RESULTS: The UM was indicated for repair of all Crawford extents including juxtarenal, pararenal, and short-neck infrarenal aneurysms (<10 mm) in 126 consecutive patients. Patients were not excluded from the study based on presentation, extent of aneurysm or dissection, or history of a spinal cord event. Patients with a thoracoabdominal aortic aneurysm were categorized by Crawford classification: types I and V (3.3%, n = 4), type II (3.3%, n = 4), type III (1%, n = 1), and type IV (93.3%, n = 117). The type IV classification patients were further categorized with 33 (28.2%) true type IV, 68 (58.1%) pararenal or infrarenal, and 16 (13.7%) with dissection. Technical success was 99.2% (n = 125). The most common major adverse event within both 30 days and 365 days of all patients was respiratory failure (11.9%, n = 15, and 13.5%, n = 17, respectively). One patient (0.8%) experienced persistent paraplegia at 365 days. Reintervention for patients at 365 days was 5.6% (n = 7). Of the 444 branches stented, the primary patency rate was remarkably high as only three patients (2.4%) required reintervention due to loss of limb patency within 365 days. Aneurysm enlargement (≥5 mm) occurred in 1.6% (n = 2) patients, and no patients experienced aneurysm rupture. No patients underwent conversion to open repair. The aneurysm-related mortality at 365 days for all patients was 4.0% (n = 5), whereas all-cause mortality was 16.7% (n = 21). Physician-modified endograft device integrity failure was not observed in any patient. CONCLUSIONS: The UM device demonstrated remarkable technical surgical success, treatment success, and device patency rates with very reasonable major adverse events and reintervention rates. This study is the most representative example of the general population in comparison with other studies of off-the-shelf devices, with 126 consecutive all-comer patients with diverse pathologies.
引用
- Tessendorf CD, Holmes A, Lucas SJ, et al. Thoracoabdominal aneurysm repair using the Unitary Manifold Device. J Vasc Surg. 2024. PMID: 38552883. doi:10.1016/j.jvs.2024.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。